NCI Community Oncology Research Program

EAQ223/SUPPORT

For Black and Latino Patients with Cancer

Please Enroll Your Eligible Patients!

EAQ223 Available Through ECOG-ACRIN Cancer Research Group

The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

Patient Population

See protocol section 3 for complete eligibility criteria

All study activities will take place at participating EA-member NCORP sites, encompassing locations across the United States.

Eligibility Criteria for Aim 2 (Providers):

- Must be a provider who specializes in medical oncology, surgery, or radiation oncology
- Must be employed at one of the participating NCORP sites

Eligibility Criteria for Aim 2 (Patients):

- Must be ≥ 18 years of age
- Must self-identify as Black and/or Latino
- Must be an oncology patient at a participating NCORP
- Must be presumed eligible (e.g. at the chart level screening) to participate in a NCI-supported clinical trial
- Must have the ability to understand and the willingness to sign a consent document
- Must be receiving care at a participating NCORP affiliated community oncology site
- Must be English or Spanish speaking
- Must have access to a landline, smartphone, computer, or tablet

Methodology Plan

See protocol section 5 for study approach details

- The SUPPORT study is a hybrid type 1 cluster randomized roll-out effectiveness-implementation trial; sites will be randomized to 1 of 3 waves to stagger the timing of the start of the SUPPORT intervention
- Sites will move sequentially through 3 stages:
  - ◊ Stage 1: baseline data collection
  - ◊ Stage 2: SUPPORT intervention implementation
  - ◊ Stage 3: post-intervention follow-up
- Cross-sectional assessments (surveys and medical records review) will be conducted among enrolled participants at Stage 1 and then at 12 months (Stages 2/3)
- SUPPORT navigators will work remotely with NCORP site research staff to screen patients for study eligibility in the EHR and assemble biweekly rosters of potential patients with upcoming appointments; Site-based research staff will recruit patients by phone, confirm eligibility using established screeners, provide study information, and obtain informed consent and contact info. Enrolled participants will be invited to participate in the baseline CT knowledge survey within 1 week
- **Stage 1: baseline control period and approach for localized intervention preparation**
  - ◊ 4-month "usual care" control period; champion and site implementation team identified
  - ◊ Conduct SUPPORT baseline assessments
- **Stage 2: 1 year of SUPPORT intervention at sites**
  - ◊ Champion/implementation team complete steps in the Tailored Action Plan to implement SUPPORT CT Literacy Tool and CT Resource Navigators (see protocol for a typical SUPPORT intervention "use case")
- **Stage 3: Sustainability and post-intervention assessments**
  - ◊ RAs to collect effectiveness outcomes data through patient surveys at 12 months
  - ◊ Develop sustainability plans; implementation evaluation

Study Chair:
Melissa A. Simon, MD, MPH

Study Co-Chairs:
Elyse R. Park, PhD, MPH
Giselle K. Perez, PhD

Patient Enrollment (Oncology Patient Enrollment Network [OPEN])

https://open.ctsu.org/open 1-888-823-5923

Protocol Information (ECOG-ACRIN Operations – Boston)

http://ecog-acrin.org (Member Login) 1-857-504-2900

ECOG-ACRIN cancer research group

EAQ223

Study Schema



N = 500 patients

Refer to the protocol for the patient and provider schemas.